We are live on
!
Find out more
BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$1.11B
1-Year Est. Return
171.34%
This Fund
S&P 500
This Quarter
Est. Return
+78.25%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$955M
AUM Growth
+$363M
(+61%)
Cap. Flow
+$73.5M
Cap. Flow
% of AUM
7.7%
Top 10 Holdings %
Top 10 Hldgs %
91.54%
Holding
15
New
4
Increased
1
Reduced
3
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRSN
Mersana Therapeutics
MRSN
|
+$47.1M |
| 2 |
Spyre Therapeutics
SYRE
|
+$20.6M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$18.3M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
+$18.1M |
| 5 |
DVAX
Dynavax Technologies
DVAX
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$28.9M |
| 2 |
Replimune Group
REPL
|
+$12M |
| 3 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
+$502K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $306M | 32.03% |
7,281,307
| – | – |
|
2
Arcutis Biotherapeutics
ARQT
$3.18B
| $120M | 12.6% |
3,979,292
| – | – |
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $104M | 10.85% |
4,080,237
| – | – |
|
|
DVAX
4
DELISTED
Dynavax Technologies
DVAX
| $96.6M | 10.12% |
10,895,773
+2,165,066
| +25% | +$10.9M |
|
|
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
| $80.6M | 8.44% |
+137,827
| New | +$47.1M |
|
|
6
Replimune Group
REPL
$1.01B
| $53.7M | 5.63% |
2,162,598
-676,370
| -24% | -$12M |
|
|
CNST
7
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $42.1M | 4.41% |
1,400,000
-803,529
| -36% | -$28.9M |
|
|
8
Spyre Therapeutics
SYRE
$9.25B
| $25M | 2.62% |
+108,000
| New | +$20.6M |
|
|
APTX
9
DELISTED
Aptinyx Inc. Common Stock
APTX
| $23.2M | 2.43% |
5,558,425
| – | – |
|
10
Savara
SVRA
$1.19B
| $23M | 2.41% |
5,128,593
| – | – |
|
|
SAGE
11
DELISTED
Sage Therapeutics
SAGE
| $20.8M | 2.17% |
+499,100
| New | +$18.1M |
|
|
12
Crinetics Pharmaceuticals
CRNX
$8.92B
| $18.8M | 1.97% |
+1,071,428
| New | +$18.3M |
|
13
X4 Pharmaceuticals
XFOR
$460M
| $15.4M | 1.61% |
54,950
| – | – |
|
|
MRNS
14
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $14.5M | 1.52% |
1,431,059
-54,625
| -4% | -$502K |
|
15
Solid Biosciences
SLDB
$900M
| $11.3M | 1.19% |
258,078
| – | – |
|
Similar funds
SL
JTWM
RWM
EIA
HH
RIM
YL
FLAM
Bain Capital Life Sciences Investors's Q2 2020 Portfolio in Review
As of Q2 2020, Bain Capital Life Sciences Investors held 15 positions worth $955M, up 61% from $591M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Bain Capital Life Sciences Investors deployed $73.5M of net new capital in Q2 2020, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Mersana Therapeutics: 137,827 shares worth $80.6M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier.
On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $28.9M trimmed.
- Bain Capital Life Sciences Investors's largest Q2 2020 buy was Mersana Therapeutics: 137,827 shares worth $80.6M.
- Bain Capital Life Sciences Investors added most to Dynavax Technologies in Q2 2020, an estimated $10.9M increase.
- Bain Capital Life Sciences Investors's biggest Q2 2020 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $28.9M.
- Bain Capital Life Sciences Investors's ten largest holdings make up 92% of its $955M portfolio in Q2 2020.
- Bain Capital Life Sciences Investors opened 4 new positions and closed 0 in Q2 2020.
- Bain Capital Life Sciences Investors's portfolio value rose 61% quarter-over-quarter to $955M.
Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2020, filed 14 Aug 2020.